Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

Table 1 Baseline characteristics of the investigated subcohort

Biomarker population	N	%
Age
Mean 64.15 years
Range 35–82 years
≤60 y	58	28.9
>60 y	143	71.1
Sex
Female	78	38.8
Male	123	61.2
Treatment arm
FUFOX	105	52.2
CAPOX	96	47.8
Localization of primary tumor
Colon	131	65.2
Rectum	61	30.3
n.k.	9	4,5
T stage at initial diagnosis
T1	1	0.4
T2	15	7.5
T3	132	65.7
T4	49	24.4
n.k.	4	2.0
N stage at initial diagnosis
N0	46	22.9
N1	57	28.3
N2	89	44.3
n.k.	9	4.5
M stage at initial diagnosis
M0*	59	29.4
M1	115	57.2
n.k.	27	13.4

*M0 indicates metachronous metastatic disease at initial diagnosis of CRC, M1 indicates synchronous metastatic disease at initial diagnosis of CRC. n.k. = not known – there were no data available.

ISSN: 1471-2407